Last update April 7, 2026

Aspirin (antiplatelet, ≤ 300 mg/day)

Compatible

Safe product and/or breastfeeding is the best option.

Nonsteroidal anti-inflammatory drug (NSAID) with antiplatelet, analgesic, anti-inflammatory, and antipyretic properties. Generally administered orally, every 24 hours and at low doses (100 to 300 mg/day) as an antiplatelet agent.

ANTI-PLATELET USE, LOW DOSES, ≤ 300 mg/day

Excreted in small amounts in breast milk (Datta 2017, Athavale 2013, Bailey 1982, Findlay 1981, Erickson 1979), but negligible when maternal doses of aspirin are less than 500 mg. (Datta 2017)

Although low plasma levels have been detected in infants (Unsworth 1987), no cases of Reye's syndrome due to aspirin through breast milk have been reported, and it is considered very unlikely to occur with isolated doses or with the low doses used in antithrombotic treatments and for anti-abortion purposes.

Various medical societies, experts, and expert consensus groups consider the occasional isolated use or antiplatelet doses of aspirin during breastfeeding to be safe or probably safe. (Bitencourt 2018, Datta 2017, Noviani 2016, Rowe 2013, Sachs 2013, Bates 2012, Bell 2011, Chen 2010, Bar-Oz 2003, WHO 2002, Spigset 2000)


See below the information of this related product:

Alternatives

We do not have alternatives for Aspirin (antiplatelet, ≤ 300 mg/day) since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Aspirin (antiplatelet, ≤ 300 mg/day) is also known as


Aspirin (antiplatelet, ≤ 300 mg/day) in other languages or writings:

Group

Aspirin (antiplatelet, ≤ 300 mg/day) belongs to this group or family:

Tradenames

Main tradenames from several countries containing Aspirin (antiplatelet, ≤ 300 mg/day) in its composition:

List of 28 tradenames
  • AAS (Portugal)™
  • Adiro™
  • AspiRoza (АспіРоза)™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Aspifox™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Bioplak™
  • CardioVent3™
  • Cardioaspirina™
  • Cardiprin™
  • Clivas Duo (Клівас Дуо)™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Compiros™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Disgren™
  • DuoPlavin™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Ecotrin™
  • Estasp™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Godamed™
  • HerzASS™
  • Nu-Seals™
  • Omnipil™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Resitune™
  • Roasax™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Rocilik™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Rosu-Asa™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • RosuASS™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Rozzor (Роззор)™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Thrombo AS™
  • Trinomia™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Trinomia (Триномія)™. Contains other elements than Aspirin (antiplatelet, ≤ 300 mg/day) in its composition
  • Tromalyt™

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 40 - 75 %
Molecular weight 180 daltons
Protein Binding 70 - 95 %
VD 0.15 l/Kg
Tmax 1 - 2 hours
T½ 7 (3 - 10) hours
M/P ratio 0.03 - 0.34 -
Relative Dose 0.3 - 0.4 %

References

  1. Bitencourt N, Bermas BL. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding. Paediatr Drugs. 2018 Dec;20(6):511-521. Abstract
  2. Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Transfer of Low Dose Aspirin Into Human Milk. J Hum Lact. 2017 May;33(2):296-299. Abstract
  3. Noviani M, Wasserman S, Clowse ME. Breastfeeding in mothers with systemic lupus erythematosus. Lupus. 2016 Aug;25(9):973-9. Abstract
  4. Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. Eur J Clin Pharmacol. 2014 Abstract
  5. Athavale MA, Maitra A, Patel S, Bhate VR, Toddywalla VS. Development of an in vitro cell culture model to study milk to plasma ratios of therapeutic drugs. Indian J Pharmacol. 2013 Abstract Full text (link to original source) Full text (in our servers)
  6. Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013 Sep;132(3):e796-809. Abstract Full text (link to original source) Full text (in our servers)
  7. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  8. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-e736S. Abstract Full text (link to original source) Full text (in our servers)
  9. Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, Kraw ME, Lindsay TF, Love MP, Pannu N, Rabasa-Lhoret R, Shuaib A, Teal P, Théroux P, Turpie AG, Welsh RC, Tanguay JF. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol. 2011 Abstract
  10. Chen LH, Zeind C, Mackell S, LaPointe T, Mutsch M, Wilson ME. Breastfeeding travelers: precautions and recommendations. J Travel Med. 2010 Jan-Feb;17(1):32-47. Abstract Full text (in our servers)
  11. Bar-Oz B, Bulkowstein M, Benyamini L, Greenberg R, Soriano I, Zimmerman D, Bortnik O, Berkovitch M. Use of antibiotic and analgesic drugs during lactation. Drug Saf. 2003 Abstract
  12. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)
  13. Spigset O, Hägg S. Analgesics and breast-feeding: safety considerations. Paediatr Drugs. 2000 Abstract
  14. Unsworth J, d'Assis-Fonseca A, Beswick DT, Blake DR. Serum salicylate levels in a breast fed infant. Ann Rheum Dis. 1987 Aug;46(8):638-9. Abstract Full text (link to original source)
  15. Bailey DN, Weibert RT, Naylor AJ, Shaw RF. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. J Anal Toxicol. 1982 Abstract
  16. Findlay JW, DeAngelis RL, Kearney MF, Welch RM, Findlay JM. Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther. 1981 May;29(5):625-33. Abstract
  17. Erickson SH, Oppenheim GL. Aspirin in breast milk. J Fam Pract. 1979 Abstract

Total visits

2,773

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM